All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The 237 antibody is a model murine monoclonal scFv, it recognizes a mutated glycopeptide expressed by an aggressive murine fi brosarcoma tumor cell line called Ag104a. The tumor-specifi c glycopeptide is generated as a result of a mutated chaperone protein Cosmc that when repaired, ablates the 237 neo-epitope. Ag104A cells express both the OTS8 transmembrane protein and a mutated Cosmcchaperone, resulting in naturally high levels of expression of the 237 epitope.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-MZ103 | Anti-237 epitope (237) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 237 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION